Drug Trial Radar · NCT04569227
Prevention of COVID-19 Infection to Severe Pneumonia or ARDS
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 30, 2026
Primary completion
Dec 30, 2027
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- Enzychem Lifesciences CorporationIndustry
- Sponsor type
- Industry
- First posted
- Sep 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19
Conditions
- Covid19 Pneumonia
Interventions
EC-18Drug
2000 mg PO daily
PlaceboDrug
PO daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients alive and free of respiratory failure through at Day 28Time frame: 28 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Lincoln Medical Center
The Bronx, New York
Kent County Memorial Hospital
Warwick, Rhode Island
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.